The GLP-1 gastrointestinal injury MDL includes claims involving Novo Nordisk and Eli Lilly products
Neither was the body weight of the rat measured before and after the microdialysis experiments
As with all therapeutic proteins, there is potential for immunogenicity
Intestinal inflammation and compromised epithelial barrier integrity accelerate the systemic dissemination of bacterially derived uremic toxins such as IS, PCS, and TMAO, which induce oxidative stress and cause progressive renal damage
Drug conjugation strategies include covalent or non-covalent attachment of the therapeutic to the carrier, ensuring stability in circulation
#SunPharma #Semaglutide #GLP1 #GenericMedicines #SouthAfrica #Pharmaceuticals #PharmaNews #GlobalHealth #LifeSciences #NAVLINDaily Sun Pharma Launches Generic Semaglutide in South Africa Sun Pharma Readies Generic Semaglutide Launch in South Africa Sun Pharma to launch its generic semaglutide injection in South Africa in the coming days for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise The launch follows approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market the product in the country South Africa is the second market, after India, where Sun Pharma has received approval for generic semaglutide
